Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowNet Cash FlowNet IncomeOther financing activitiesShare-based CompensationShares IssuedShares Repurchased
Daily Values
Growth Metrics
Income Statement
Others
Ratios

C4 Therapeutics (CCCC) Net Income: 2019-2024

Historic Net Income for C4 Therapeutics (CCCC) over the last 6 years, with Dec 2024 value amounting to -$105.3 million.

  • C4 Therapeutics' Net Income fell 30.41% to -$32.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$119.1 million, marking a year-over-year decrease of 12.88%. This contributed to the annual value of -$105.3 million for FY2024, which is 20.51% up from last year.
  • According to the latest figures from FY2024, C4 Therapeutics' Net Income is -$105.3 million, which was up 20.51% from -$132.5 million recorded in FY2023.
  • C4 Therapeutics' Net Income's 5-year high stood at -$66.3 million during FY2020, with a 5-year trough of -$132.5 million in FY2023.
  • For the 3-year period, C4 Therapeutics' Net Income averaged around -$122.0 million, with its median value being -$128.2 million (2022).
  • Per our database at Business Quant, C4 Therapeutics' Net Income slumped by 94.54% in 2020 and then climbed by 20.51% in 2024.
  • Yearly analysis of 5 years shows C4 Therapeutics' Net Income stood at -$66.3 million in 2020, then dropped by 26.47% to -$83.9 million in 2021, then crashed by 52.79% to -$128.2 million in 2022, then declined by 3.37% to -$132.5 million in 2023, then grew by 20.51% to -$105.3 million in 2024.